

Serial No. 09/209,799

claims recite the optional addition of ammonium sulfate or zinc. The amendment presented above deletes ammonium sulfate from claims 33 and 39. New Claims 77 through 79 recite the optional addition of ammonium sulfate. Claim 36 was deleted and is now presented as new Claim 78. Claims 40 and 75 add the limitation that the composition contain a "pharmaceutically acceptable carrier." Pharmaceutically acceptable carriers are discussed in the Specification on page 13, line 3.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

August 8, 2001

G

Serial No. 09/209,799

Attachment

**Marked-up copy of the amendments as required by
37 C.F.R. 1.121(b) (1) (iii)**

33. (twice amended) Flat rod shaped or plate-like Val-8-Glucagon-like peptide-1(7-37)OH crystals [of a peptide having the amino acid sequence] of SEQ ID NO:5 prepared by crystallizing the peptide from an aqueous solution comprising the peptide and between about 2-15% (v/v) ethanol or [between about 2-15% (v/v)] propanol, [and wherein] the solution optionally comprising [comprises ammonium sulfate or] zinc and [provided that] the crystals vary in size from between about 2-25 microns by 10-150 microns with a depth from about 0.5-5 microns.
34. (twice amended) The crystals of Claim 33 wherein [the concentration of] the peptide in the solution is between about 1-10 mg/ml and [the] pH [of the solution] is between about 6 and 7.
35. (twice amended) The crystals of Claim 34 wherein the [concentration of] peptide in the solution is between about 2-7 mg/ml and the ethanol is [solution comprises] between about 3-13% [ethanol] (v/v).
37. (twice amended) The crystals of Claim 33 wherein the [concentration of] peptide in the solution is between about 1-20 mg/mL[,] and [the] molar ratio of zinc to peptide is between about 0.5 to 1.7[,] and [the] pH [of the solution] is between about 7-10.
38. (twice amended) The crystals of Claim 37 wherein the [concentration of] peptide in the solution is between about 2-10 mg/mL[,] and [the] molar ratio of zinc to peptide is between about 0.6 to 1.5[,] and [the] pH of [the solution] is between about 7.2-9.7.

Serial No. 09/209,799

39. (twice amended) Flat rod shaped or plate-like Val-8-Glucagon-like Peptide-1(7-37)OH crystals [of a peptide having the amino acid sequence] of SEQ ID NO:5 prepared by crystallizing the peptide from an aqueous solution comprising the peptide and between about 2-15% (w/v) of a mono or disaccharide selected from trehalose, mannitol, glucose, erythrose, ribose, galactose, fructose, maltose, ⁴ sucrose or lactose[;], [and wherein] the solution optionally comprising [comprises ammonium sulfate or] ¹⁰ zinc and [provided that] the crystals vary in size from between about 2-25 microns by 10-150 microns with a depth from about 0.5-5 microns.
40. (twice amended) A composition comprising the crystals of Claim 33 and a pharmaceutically acceptable carrier.
42. The composition of Claim 40 [wherein the composition additionally comprises] comprising zinc.
75. (amended) A composition comprising the crystals of Claim 39 and a pharmaceutically acceptable carrier.
76. The composition of Claim 75 [wherein the composition additionally comprises] comprising zinc.
77. (new) Flat rod shaped or plate-like Val-8-Glucagon-like peptide-1(7-37)OH crystals [of a peptide having the amino acid sequence] of SEQ ID NO:5 prepared by crystallizing the peptide from an aqueous solution comprising the peptide and between about 2-15% (v/v) ethanol or propanol, [and] the solution optionally comprising [comprises] ammonium sulfate and the crystals vary in size from between about 2-25 microns by 10-150 microns with a depth from about 0.5-5 microns.

G

Serial No. 09/209,799

78. (new) The crystals of Claim 77 wherein the ammonium sulfate is about 1% (w/v).
79. (new) Flat rod shaped or plate-like Val-8-Glucagon-like peptide-1(7-37)OH crystals [of a peptide having the amino acid sequence] of SEQ ID NO:5 prepared by crystallizing the peptide from an aqueous solution comprising the peptide and between about 2-15% (w/v) of a mono or disaccharide selected from trehalose, mannitol, glucose, erythrose, ribose, galactose, fructose, maltose, sucrose or lactose, [and] the solution optionally comprising [comprises] ammonium sulfate and the crystals vary in size from between about 2-25 microns by 10-150 microns with a depth from about 0.5-5 microns.